Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strongly increased exposure of meloxicam in CYP2C93/3 individuals.

Pharmacogenetics and genomics - 1 Feb 2014

Lee Hye-In, Bae Jung-Woo, Choi Chang-Ik, Lee Yun-Jeong, Byeon Ji-Yeong, Jang Choon-Gon, Lee Seok-Yong

Abstract excerpt

OBJECTIVE: The effects of CYP2C9*1/*3 and *3/*3 genotypes on the pharmacokinetics and pharmacodynamics of meloxicam were evaluated in healthy Korean subjects. METHODS: After oral administration of 15 mg meloxicam, the plasma concentrations of meloxicam were assessed in 11 CYP2C9*1/*1 individuals, eight CYP2C9*1/*3 individuals, and three CYP2C9*3/*3 individuals. The pharmacodynamic effects were determined by...

Topics

Join the communities discussing this publication.

Anti-Inflammatory Agents, Non-Steroidal
Aryl Hydrocarbon Hydroxylases
Asian People
Cytochrome P-450 CYP2C9
Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Metabolic Clearance Rate

Polymorphism, Genetic

Source

Identifiers

PMID: 24322170
DOI: 10.1097/FPC.0000000000000025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.PMID 24322170Read ↗

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.Semantic proximity Read ↗

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.Semantic proximity Read ↗

Effect of the CYP2C9*3 allele on lornoxicam metabolism.Semantic proximity Read ↗

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Semantic proximity Read ↗

Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.Semantic proximity Read ↗

Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Semantic proximity Read ↗

The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem.Semantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.